The closing price of Apellis Pharmaceuticals Inc (NASDAQ: APLS) was $49.50 for the day, up 0.81% from the previous closing price of $49.10. In other words, the price has increased by $+0.40 from its previous closing price. On the day, 921380 shares were traded. APLS stock price reached its highest trading level at $49.52 during the session, while it also had its lowest trading level at $47.90.
Our analysis of APLS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.76 and its Current Ratio is at 4.29. In the meantime, Its Debt-to-Equity ratio is 1.94 whereas as Long-Term Debt/Eq ratio is at 1.72.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on November 09, 2023, initiated with a Buy rating and assigned the stock a target price of $74.
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 17 when Machiels Alec sold 1,250 shares for $47.74 per share. The transaction valued at 59,675 led to the insider holds 367,420 shares of the business.
Deschatelets Pascal sold 12,000 shares of APLS for $567,240 on Nov 08. The Chief Scientific Officer now owns 1,071,807 shares after completing the transaction at $47.27 per share. On Oct 23, another insider, Chopas James George, who serves as the VP/Chief Accounting Officer of the company, sold 132 shares for $46.04 each. As a result, the insider received 6,077 and left with 32,680 shares of the company.
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APLS now has a Market Capitalization of 5.87B and an Enterprise Value of 5.53B. For the stock, the TTM Price-to-Sale (P/S) ratio is 21.50 while its Price-to-Book (P/B) ratio in mrq is 25.22. Its current Enterprise Value per Revenue stands at 20.25 whereas that against EBITDA is -9.61.
Stock Price History:
Over the past 52 weeks, APLS has reached a high of $94.75, while it has fallen to a 52-week low of $19.83. The 50-Day Moving Average of the stock is 45.13, while the 200-Day Moving Average is calculated to be 60.85.
APLS traded an average of 2.60M shares per day over the past three months and 2.02M shares per day over the past ten days. A total of 110.77M shares are outstanding, with a floating share count of 96.74M. Insiders hold about 18.36% of the company’s shares, while institutions hold 93.70% stake in the company. Shares short for APLS as of Oct 30, 2023 were 16.23M with a Short Ratio of 16.23M, compared to 16.77M on Sep 28, 2023. Therefore, it implies a Short% of Shares Outstanding of 13.70% and a Short% of Float of 15.94%.
The firm’s stock currently is rated by 14 analysts. On average, analysts expect EPS of -$0.87 for the current quarter, with a high estimate of -$0.56 and a low estimate of -$1.12, while EPS last year was -$1.5. The consensus estimate for the next quarter is -$0.67, with high estimates of -$0.19 and low estimates of -$1.
Analysts are recommending an EPS of between -$4.29 and -$4.97 for the fiscal current year, implying an average EPS of -$4.62. EPS for the following year is -$1.7, with 14 analysts recommending between $0.9 and -$3.01.
It is expected that $90B in revenue will be generated in the current quarter, according to 14 analysts. It ranges from a high estimate of $143.72M to a low estimate of $86.59M. As of the current estimate, Apellis Pharmaceuticals Inc’s year-ago sales were $22.66M, an estimated increase of 434.70% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $134.93M, an increase of 200.90% less than the figure of $434.70% in the same quarter last year. There is a high estimate of $177.4M for the next quarter, whereas the lowest estimate is $84.01M.
A total of 15 analysts have provided revenue estimates for APLS’s current fiscal year. The highest revenue estimate was $393.94M, while the lowest revenue estimate was $336.8M, resulting in an average revenue estimate of $369.94M. In the same quarter a year ago, actual revenue was $75.42M, up 390.50% from the average estimate. Based on 15 analysts’ estimates, the company’s revenue will be $621.09M in the next fiscal year. The high estimate is $869.45M and the low estimate is $399.42M. The average revenue growth estimate for next year is up 67.90% from the average revenue estimate for this year.